Xiangxue Pharmaceutical Co.,Ltd. (300147.SZ)
CNY 12.14
(2.53%)
CNY 12.14
(2.53%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 590.91 Million CNY | 30.78% |
| 2022 | 451.85 Million CNY | -14.95% |
| 2021 | 531.28 Million CNY | -43.89% |
| 2020 | 946.91 Million CNY | 0.93% |
| 2019 | 938.2 Million CNY | -28.29% |
| 2018 | 1.3 Billion CNY | -28.18% |
| 2017 | 1.82 Billion CNY | 141.6% |
| 2016 | 754 Million CNY | 51.11% |
| 2015 | 498.97 Million CNY | -7.06% |
| 2014 | 536.89 Million CNY | -25.0% |
| 2013 | 715.81 Million CNY | 6.09% |
| 2012 | 674.73 Million CNY | 274.85% |
| 2011 | 180 Million CNY | 323.53% |
| 2010 | 42.5 Million CNY | 0.0% |
| 2009 | 42.5 Million CNY | -32.0% |
| 2008 | 62.5 Million CNY | -28.57% |
| 2007 | 87.5 Million CNY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q3 | 578.48 Million CNY | 17.37% |
| 2024 Q1 | 579.56 Million CNY | -1.57% |
| 2024 Q2 | 526.7 Million CNY | -9.94% |
| 2023 Q4 | 590.91 Million CNY | -28.66% |
| 2023 FY | 590.91 Million CNY | 30.78% |
| 2023 Q1 | 449.02 Million CNY | -0.63% |
| 2023 Q2 | 803.57 Million CNY | 78.96% |
| 2023 Q3 | 828.31 Million CNY | 3.08% |
| 2022 Q4 | 451.85 Million CNY | -11.51% |
| 2022 FY | 451.85 Million CNY | -14.95% |
| 2022 Q2 | 546.67 Million CNY | -11.62% |
| 2022 Q3 | 510.59 Million CNY | -6.6% |
| 2022 Q1 | 618.56 Million CNY | 16.43% |
| 2021 Q3 | 864.24 Million CNY | -1.51% |
| 2021 FY | 531.28 Million CNY | -43.89% |
| 2021 Q4 | 531.28 Million CNY | -38.53% |
| 2021 Q1 | 1.03 Billion CNY | 8.9% |
| 2021 Q2 | 877.53 Million CNY | -14.9% |
| 2020 Q1 | 963.55 Million CNY | 2.7% |
| 2020 Q4 | 946.91 Million CNY | -4.47% |
| 2020 FY | 946.91 Million CNY | 0.93% |
| 2020 Q2 | 976.22 Million CNY | 1.32% |
| 2020 Q3 | 991.18 Million CNY | 1.53% |
| 2019 Q3 | 1.56 Billion CNY | 3.76% |
| 2019 Q4 | 938.2 Million CNY | -40.2% |
| 2019 Q1 | 1.3 Billion CNY | -0.09% |
| 2019 Q2 | 1.51 Billion CNY | 15.67% |
| 2019 FY | 938.2 Million CNY | -28.29% |
| 2018 Q1 | 1.84 Billion CNY | 1.54% |
| 2018 Q3 | 2 Billion CNY | -3.51% |
| 2018 FY | 1.3 Billion CNY | -28.18% |
| 2018 Q4 | 1.3 Billion CNY | -34.76% |
| 2018 Q2 | 2.07 Billion CNY | 12.36% |
| 2017 Q2 | 818.5 Million CNY | 5.61% |
| 2017 Q3 | 854.5 Million CNY | 4.4% |
| 2017 Q4 | 1.82 Billion CNY | 113.19% |
| 2017 FY | 1.82 Billion CNY | 141.6% |
| 2017 Q1 | 775 Million CNY | 2.79% |
| 2016 Q1 | 499.24 Million CNY | 0.05% |
| 2016 FY | 754 Million CNY | 51.11% |
| 2016 Q4 | 754 Million CNY | -39.56% |
| 2016 Q2 | 499.51 Million CNY | 0.05% |
| 2016 Q3 | 1.24 Billion CNY | 149.77% |
| 2015 Q1 | 537.16 Million CNY | 0.05% |
| 2015 Q4 | 498.97 Million CNY | -7.2% |
| 2015 FY | 498.97 Million CNY | -7.06% |
| 2015 Q2 | 537.43 Million CNY | 0.05% |
| 2015 Q3 | 537.7 Million CNY | 0.05% |
| 2014 Q3 | 606.62 Million CNY | -14.72% |
| 2014 Q2 | 711.35 Million CNY | 0.04% |
| 2014 Q1 | 711.08 Million CNY | -0.66% |
| 2014 FY | 536.89 Million CNY | -25.0% |
| 2014 Q4 | 536.89 Million CNY | -11.49% |
| 2013 Q1 | 670 Million CNY | -0.7% |
| 2013 FY | 715.81 Million CNY | 6.09% |
| 2013 Q2 | 620.27 Million CNY | -7.42% |
| 2013 Q4 | 715.81 Million CNY | 6.94% |
| 2013 Q3 | 669.34 Million CNY | 7.91% |
| 2012 FY | 674.73 Million CNY | 274.85% |
| 2012 Q1 | 180 Million CNY | 0.0% |
| 2012 Q2 | 80 Million CNY | -55.56% |
| 2012 Q3 | 180 Million CNY | 125.0% |
| 2012 Q4 | 674.73 Million CNY | 274.85% |
| 2011 Q3 | 180 Million CNY | 0.0% |
| 2011 Q1 | 42.5 Million CNY | 0.0% |
| 2011 FY | 180 Million CNY | 323.53% |
| 2011 Q4 | 180 Million CNY | 0.0% |
| 2011 Q2 | 180 Million CNY | 323.53% |
| 2010 Q3 | 25 Million CNY | -16.67% |
| 2010 FY | 42.5 Million CNY | 0.0% |
| 2010 Q2 | 30 Million CNY | 0.0% |
| 2010 Q4 | 42.5 Million CNY | 70.0% |
| 2009 Q4 | 42.5 Million CNY | 0.0% |
| 2009 FY | 42.5 Million CNY | -32.0% |
| 2008 FY | 62.5 Million CNY | -28.57% |
| 2007 FY | 87.5 Million CNY | 0.0% |